Puma Biotechnology, Inc. (PBYI) Stock Forecast
PBYI analyst forecast
as of October 18, 2026- Analyst consensus
- —
- Price target
- $6.00 average of analyst targets
- Upside to target
- −39.0% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $0.06
- 52-week range
- $4.73 – $10.52
PBYI price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PBYI earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.12 | $0.12 | $0.12 | $0.21 | −42.9% | 1 |
| Current fiscal year (2026) | $0.55 | $0.55 | $0.55 | $0.75 | −26.7% | 1 |
| Next fiscal year (2027) | $0.35 | $0.35 | $0.35 | $0.55 | −36.4% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PBYI revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $57.5M | $57.5M | $57.5M | +5.5% | 1 |
| Current fiscal year (2026) | $0 | $0 | $0 | −1.1% | — |
| Next fiscal year (2027) | $0 | $0 | $0 | +1.3% | — |
PBYI EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PBYI EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.19 | $0.19 | $0.19 | $0.19 | $0.12 | −36.8% | 0 up · 0 down |
| Current fiscal year (2026) | $0.45 | $0.45 | $0.45 | $0.45 | $0.55 | +22.2% | 1 up · 0 down |
| Next fiscal year (2027) | $0.35 | $0.35 | $0.35 | $0.35 | $0.35 | 0.0% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PBYI earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PBYI beat in 11 of 12.
What analysts expect from PBYI
The average price target is $6.00, 39.0% below the latest close of $9.83. Analysts expect earnings of $0.55 per share for 2026, −26.7% from a year earlier. For 2027 the average estimate is $0.35 per share. Puma Biotechnology beat the EPS estimate in 11 of the last 12 quarters.
Related: PBYI income statement, PBYI key metrics, PBYI chart. See the PBYI stock overview for the latest quote and news.
PBYI forecast FAQ
What is Puma Biotechnology's price target?
The average analyst price target for Puma Biotechnology is $6.00, 39.0% below the latest close of $9.83.
What is Puma Biotechnology's EPS forecast?
Analysts forecast $0.55 per share for 2026 (range $0.55 to $0.55); for 2027 the estimate is $0.35.
When does Puma Biotechnology report earnings?
Puma Biotechnology is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $0.06.
Does Puma Biotechnology usually beat earnings estimates?
Puma Biotechnology reported EPS at or above the analyst estimate in 11 of the last 12 quarters.